|
C9ORF41 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 7.57639999959814E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
9.50920000000188E-05 |
| Normal-vs-Stage2 |
6.605100E-04 |
| Normal-vs-Stage3 |
5.98689999797841E-08 |
| Normal-vs-Stage4 |
2.49029999954686E-07 |
| Stage1-vs-Stage2 |
7.951800E-01 |
| Stage1-vs-Stage3 |
5.648200E-02 |
| Stage1-vs-Stage4 |
3.339900E-02 |
| Stage2-vs-Stage3 |
3.034800E-01 |
| Stage2-vs-Stage4 |
1.890790E-01 |
| Stage3-vs-Stage4 |
6.083200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
8.56049999997666E-07 |
| Normal-vs-AfricanAmerican |
3.497600E-02 |
| Normal-vs-Asian |
1.58352999999334E-05 |
| Caucasian-vs-AfricanAmerican |
3.257000E-01 |
| Caucasian-vs-Asian |
4.961200E-01 |
| AfricanAmerican-vs-Asian |
1.791170E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.1227000440428E-09 |
| Normal-vs-Female |
4.1151000000017E-05 |
| Male-vs-Female |
6.079100E-03 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.406300E-04 |
| Normal-vs-Age(41-60Yrs) |
3.31450000001787E-07 |
| Normal-vs-Age(61-80Yrs) |
6.45369999996426E-07 |
| Normal-vs-Age(81-100Yrs) |
4.617600E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.839570E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.324220E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.910200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.409000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.431600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.603600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.462000E-02 |
| Classical-VS-Follicular |
1.740960E-01 |
| Classical-VS-Other |
1.082230E-01 |
| Classical-VS-Normal |
6.15870000000296E-05 |
| Tall-VS-Follicular |
3.980200E-01 |
| Tall-VS-Other |
3.754600E-01 |
| Tall-VS-Normal |
1.59113999999017E-05 |
| Follicular-VS-Other |
2.790600E-01 |
| Follicular-VS-Normal |
2.13369999999546E-05 |
| Other-VS-Normal |
1.497040E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.42580000001202E-06 |
| Normal-vs-N1 |
1.02989999994918E-06 |
| N0-vs-N1 |
1.829830E-01 |
|
|
